Abivax is trading 4.51% down at $94.55 on October 1, 2026; the available evidence does not establish a specific catalyst. - Its September 30 release announced plans to present obefazimod data at UEG Week, but the event does not clearly explain the decline. - Rising Treasury yields and a cautious market may be contributing; major-index moves were smaller than Abivax’s drop.